# A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

> **NCT01975831** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 104 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Cervical Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT01975831
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-19
- **Primary completion:** 2019-12
- **Final completion:** 2021-07-02
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01975831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01975831, "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01975831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*